Tempest Therapeutics, Inc. (TPST)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Tempest Therapeutics, Inc. — 424B3 Filing
# 🧾 What This Document Is This is a prospectus filing with the SEC. Its main job is to let certain investors ("selling stockholders") legally resell up to **2,777,781 shares** of Tempest Therapeutics' common stock to the public. Think of it as a "resale permit" for these specific shares. 👉 **The
Tempest Therapeutics, Inc. — 424B3 Filing
# 🔥 What This Document Is This is a **prospectus**, a legal document that registers shares for resale. Tempest Therapeutics (ticker: TPST) is filing this so a group of "selling stockholders" can sell up to **8,268,495 shares** of its common stock on the open market. These shares weren't just printe
SEC filings
All filings →Insider trades
All insider trades →Tempest Therapeutics, Inc. has no reported insider trades in the last 90 days.